Jingfeng pharmaceutical has another new drug of over 100 million class approved for market in the United States

Today, Jingfeng pharmaceutical announced that recently, sungen Pharma, a holding subsidiary of Hunan Jingfeng Pharmaceutical Co., Ltd (hereinafter referred to as "the company"), LLC (hereinafter referred to as "Shangjin") received a notice from the U.S Food and Drug Administration (the U.S FDA), and geneyork pharmaceuticals Group LLC, a joint venture of Shangjin and Tianjin Jinyao Group Co., Ltd in the U.S The abbreviated new drug application for prednisone tablet (ANDA, i.e., the application for generic drug in the United States, which is approved by the United States FDA, means that the applicant can produce and sell the product in the United States market) has been approved Prednisone tablets are used to treat the symptoms of adrenocortical hypofunction, active rheumatism, rheumatoid arthritis, systemic lupus erythematosus and so on At present, the main producers in the U.S market are westward, vintage, jubilant, Actavis, etc According to IMS data, the sales volume of prednisone tablets in the U.S market in 2017 was about $139 million, while the sales volume in the U.S market in 2016 and 2015 were $134 million and $139 million, respectively The following is the full text of the announcement: